Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Correction

Correction:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study

Samuel Frank* and Huntington Study Group/TETRA-HD Investigators

Author Affiliations

72 East Concord St., C329, Boston, MA 02118, USA

For all author emails, please log on.

BMC Neurology 2011, 11:18  doi:10.1186/1471-2377-11-18

The electronic version of this article is the complete one and can be found online at:

Received:3 February 2011
Accepted:4 February 2011
Published:4 February 2011

© 2011 Frank and Huntington Study Group/TETRA-HD Investigators; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


After publication of this work [1], we became aware of a typographical error. The term dysphagia inadvertently replaced the term dysarthria in two instances. Dysarthria was statistically significantly worsened at week 80 compared to baseline, whereas there was only a statistical trend (p = 0.10) for dysphagia at week 80 compared to baseline. Dysphagia continues to be an issue in patients with Huntington Disease and was reported as an adverse event in this study. Therefore, clinicians who prescribe tetrabenazine should still monitor their patients for worsening swallowing, but the worsening was not statistically different in those who completed this trial. No further studies of tetrabenazine in Huntington Disease have been completed since the publication of this study.

Dysarthria should be replaced for dysphagia in two places and the manuscript should read as follows:

Abstract, page 1:

Results: Parkinsonism and dysarthria scores were significantly increased at week 80 compared to baseline.

Discussion, page 8:

Although parkinsonism and dysarthria were increased in subjects at week 80, this finding was likely a result of the natural progression of disease.

The other uses of the terms dysarthria and dysphagia in the manuscript are correct. We regret the error and any inconvenince it may have caused.


  1. Frank S, Huntington Study Group/TETRA-HD Investigators: Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study.

    BMC Neurol 2009, 9:62. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here: